This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum
See You Next Year! 26-28 Feb, 2025
Westin Miyako KyotoKyoto, Japan

Rowshon Alam, Ph.D.
Senior Director, Head of Process Chemistry at Prime Medicine


Dr. Rowshon Alam is a Senior Director of Process Chemistry at Prime Medicine, where he leads the group for chemical synthesis, process optimization, scale up, and in-process analytics of long guide RNA to support pre-clinical development of various in vivo programs. Prior to Prime medicine, Rowshon worked at Wave Life Sciences for 6 years (director, process development), Nitto Denko Avecia for 5 years (group leader, process dev.) and at Alnylam for approx. 2 years (scientist, medicinal chemistry) to develop scalable process for stereo-defined oligonucleotides, siRNA, ASO with a variety of chemical modifications and ASO/siRNA conjugates with delivery ligands.

Rowshon obtained his PhD in 2000 in pharmaceutical chemistry from Kyushu University (Japan) followed by JSPS fellowship & JST, CREST fellow (2000-2003). Rowshon was a recipient of NIH fellowship at National Institutes of Health (2003-2006) where he developed triplex forming oligonucleotides (TFO) as a gene targeting reagents. He then worked as a Research Assistant Professor at the University of North Carolina at Chapel Hill (UNC-CH) for chemical synthesis of highly chemically modified ASO and ASO-conjugates (2006-2009). Rowshon was authored >20 peer-reviewed publications in the field of oligonucleotide research.

Agenda Sessions

  • Synthesizing Long Guide RNAs for In Vivo Prime Editing